Reports Q1 revenue $858.4M, consensus $850.93M. The company said, “Our goal is to develop transformative medicines for all people with CF and other serious diseases and to ensure all eligible patients have access to these medicines as quickly as possible. We have made significant progress toward achieving this goal by rapidly advancing our triple combination regimens through late-stage development, and we remain on track to submit a New Drug Application for one of these medicines in the third quarter of 2019. We also continue to advance our earlier-stage programs targeting AAT, pain, FSGS and sickle cell disease. In the first quarter, we again delivered strong revenue and earnings growth, which further enhances our ability to make significant investments in internal and external innovation.” Reports Q1 KALYDECO revenue $244M vs. $250M last year, ORKAMBI revenue $293M vs. $354M last year, and SYMDEKO/SYMKEVI revenue $320M vs. $34M last year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.